Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

Sarepta Therapeutics Stock Performance Shares of NASDAQ SRPT opened at $133.34 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25. The stock has a ...

In trading on Tuesday, shares of Sarepta Therapeutics Inc (Symbol: SRPT) crossed above their 200 day moving average of $129.96, changing hands as high as $131.00 per share. Sarepta Therapeutics ...

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT). Here's what you need to know.

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.